Patents by Inventor Scott D. Kuduk

Scott D. Kuduk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION
    Publication number: 20250011326
    Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.
    Type: Application
    Filed: May 31, 2023
    Publication date: January 9, 2025
    Inventors: Lianzhu Liu, Gang Deng, Chunliang Lu, Bingqing Tang, Zhiguo Liu, Zhanling Cheng, Sandrine Céline Grosse, Koen Vandyck, Edgar Jacoby, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Scott D. Kuduk, Lindsey Graham Deratt
  • FUSED HETEROCYCLIC DERIVATIVES
    Publication number: 20240287070
    Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.
    Type: Application
    Filed: June 1, 2022
    Publication date: August 29, 2024
    Inventors: Chunliang LU, Xiaoyu LI, Lianzhu LIU, Gang DENG, Zhiguo LIU, Bingqing TANG, Wei CAI, Zhanling CHENG, Sandrine Céline GROSSE, Koen VANDYCK, Edgar JACOBY, Tim Hugo Maria JONCKERS, Pierre Jean-Marie Bernard RABOISSON, Scott D. KUDUK, Lindsey Graham DERATT
  • FUSED HETEROCYCLIC DERIVATIVES
    Publication number: 20240279227
    Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.
    Type: Application
    Filed: June 1, 2022
    Publication date: August 22, 2024
    Inventors: Chunliang LU, Gang DENG, Lianzhu LIU, Xiaoyu LI, Zhiguo LIU, Bingqing TANG, Wei CAI, Shane PLUNKETT, Philip James PYE, Lindsey Graham DERATT, Pierre Jean-Marie Bernard RABOISSON, Edgar JACOBY, Sandrine Céline GROSSE, Zhanling CHENG, Koen VANDYCK, Tim Hugo Maria JONCKERS, Scott D. KUDUK
  • FUSED HETEROCYCLIC DERIVATIVES
    Publication number: 20220348592
    Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.
    Type: Application
    Filed: May 27, 2020
    Publication date: November 3, 2022
    Inventors: Sandrine Celine GROSSE, Scott D. KUDUK, Lindsey Graham DERATT, Koen VANDYCK, Pierre Jean-Marien Bernard RABOISSON, Serge Maria Aloysius PIETERS, Bart Rudolf Romanie KESTELEYN, Wim Gaston VERSCHUEREN, Jan Martin BERKE, Morgan Charles R. LECOMTE, Carolina MARTINEZ LAMENCA, Tim Hugo Maria JONCKERS, Gang DENG, Yimin JIANG, Yanping XU, Zhangling CHENG, Lili HU
  • FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS
    Publication number: 20220323455
    Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.
    Type: Application
    Filed: May 27, 2020
    Publication date: October 13, 2022
    Inventors: Scott D. KUDUK, Lindsey Graham DERATT, Chao-Yuan WANG, Jan Martin BERKE
  • AZEPINES AS HBV CAPSID ASSEMBLY MODULATORS
    Publication number: 20220251114
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of CAM1. Such compounds are represented by Formula (I) as follows: Wherein R1, R2, R3, R4, X, and Y are defined herein.
    Type: Application
    Filed: May 27, 2020
    Publication date: August 11, 2022
    Inventor: Scott D. KUDUK
  • FUSED HETEROCYCLE DERIVATIVES
    Publication number: 20220242879
    Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.
    Type: Application
    Filed: May 27, 2020
    Publication date: August 4, 2022
    Inventors: Scott D. KUDUK, Christelle Catherine Cecile DOEBELIN, Abdellah TAHRI, Sandrine Céline GROSSE, Stefaan Julien LAST, Lindsey Graham DERATT, Koen VANDYCK, Pierre Jean-Marie Bernard RABOISSON, Jan Martin BERKE, Wim Gaston VERSCHUEREN, Michel OBRINGER
  • DI-FLUORO AZEPANES AS HBV CAPSID ASSEMBLY MODULATORS
    Publication number: 20220235051
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of CAM1.
    Type: Application
    Filed: May 27, 2020
    Publication date: July 28, 2022
    Inventors: Scott D. KUDUK, Lindsey Graham DERATT
  • DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS
    Publication number: 20220213102
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the HBV CAM. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, X, and R4, are defined herein.
    Type: Application
    Filed: May 27, 2020
    Publication date: July 7, 2022
    Inventor: Scott D. KUDUK
  • FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS
    Publication number: 20220153754
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of CAM1. Such compounds are represented by Formula (I) as follows: wherein, R1, R1A, R2, R3, R4, HET, n, X, Y, Z1 and Z2 are defined herein.
    Type: Application
    Filed: May 27, 2020
    Publication date: May 19, 2022
    Inventor: Scott D. KUDUK
  • PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS
    Publication number: 20220064147
    Abstract: The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Application
    Filed: December 13, 2019
    Publication date: March 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Antonella Converso, Abdellatif El Marrouni, Ashley Forster, Jessica L. Frie, David N. Hunter, Scott D. Kuduk, Helen J. Mitchell, Philippe Nantermet, Deyou Sha, William Daniel Shipe, Cheng Wang, Deping Wang
  • Fused heteroaryl derivatives as orexin receptor antagonists
    Patent number: 10526336
    Abstract: The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 7, 2020
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Douglas C. Beshore, Na Meng, Yunfu Luo
  • Oxazole orexin receptor antagonists
    Patent number: 10435398
    Abstract: The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: October 8, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • Piperidine oxadiazole and thiadiazole orexin receptor antagonists
    Patent number: 10308645
    Abstract: The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: September 27, 2015
    Date of Patent: June 4, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Nigel Liverton, Scott D. Kuduk, Yunfu Luo, Na Meng, Tingting Yu
  • Heteroaryl orexin receptor antagonists
    Patent number: 10239838
    Abstract: The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • Pyrazole orexin receptor antagonists
    Patent number: 10227336
    Abstract: The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: March 12, 2019
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Nigel Liverton, Scott D. Kuduk, Yunfu Luo
  • Hydroxmethyl piperidine orexin receptor antagonists
    Patent number: 10214535
    Abstract: The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20180370973
    Abstract: The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 27, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Douglas C. Beshore, Na Meng, Yunfu Luo
  • Amidoethyl azole orexin receptor antagonists
    Patent number: 10155750
    Abstract: The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 18, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
  • Pyrrolidine orexin receptor antagonists
    Patent number: 10150751
    Abstract: The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 11, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo, Jason W. Skudlarek